Related Experiment Videos
'Beyond blood pressure' means multiple risk factor intervention, not pleiotropic antihypertensive drugs
Jan A Staessen1, Lutgarde Thijs, Yan Li
1Studies Coordinating Centre, Division of Hypertension and Cardiovascular Rehabilitation, Department of Cardiovascular Diseases, University of Leuven, Leuven, Belgium. jan.staessen@proximus.be
Insights
Newer antihypertensive drugs offer benefits beyond blood pressure lowering, but require large trials to prove. Combination therapy and lifestyle changes are key for true cardiovascular prevention in hypertension.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Antihypertensive medications are crucial for cardiovascular disease prevention.
- Understanding drug class-specific benefits beyond blood pressure reduction is essential.
Purpose of the Study:
- To evaluate the role of blood pressure lowering versus class-specific properties of antihypertensive drugs in cardiovascular prevention.
- To determine the evidence for benefits beyond blood pressure reduction with newer agents.
Main Methods:
- Review of recently published clinical trials.
- Analysis of meta-regression studies.
Main Results:
- Large patient numbers (150,000–180,000) and long follow-up (3–5 years) are needed to show 10–15% benefits beyond blood pressure lowering for newer drugs.
- Newer agents may reduce new-onset diabetes mellitus by approximately 30% compared to older drugs, averting ~3 cases per 100 patients treated for 5 years.
- Combination therapy enhances efficacy and may reduce metabolic adverse effects.
Conclusions:
- True cardiovascular benefit in hypertensive patients stems from comprehensive risk factor intervention, not solely blood pressure reduction.
- Optimizing treatment often involves rotating and combining drug classes for efficacy and tolerability.
- The clinical significance of averted iatrogenic diabetes requires further investigation.
Purpose Of Review:
We examined the role of blood pressure-lowering compared with class-specific properties of antihypertensive drugs in cardiovascular prevention.
Recent Findings:
We reviewed recently published trials and meta-regression analyses.
Summary:
From 150,000 to 180,000 randomized patients followed up from 3 to 5 years were required to demonstrate a 10-15% benefit 'beyond blood pressure lowering' of newer antihypertensive drugs, such as calcium channel blockers or angiotensin-converting enzyme inhibitors in the prevention of cause-specific cardiovascular complications. Assuming an absolute risk of new-onset diabetes mellitus on older drugs of approximately 10% over 5 years and a relative benefit on the newer drugs of approximately 30%, about 100 patients would have to be treated for 5 years with the newer agents to avert approximately three iatrogenic cases of diabetes. Whether or not new-onset diabetes is associated with increased risk is uncertain. In most patients, optimization of treatment at acceptable tolerance requires rotation through and combination of several drug classes. Combination of different classes of antihypertensive drugs not only enhances the blood pressure-lowering efficacy, but likely decreases the risk of metabolic adverse effects as well. True benefit beyond blood pressure lowering in hypertensive patients comes from multiple risk factor intervention.
Related Concept Videos
Factors affecting Blood pressure
Physiological Factors:
Hypertension IV: Drug Therapy and Lifestyle Modifications
Hypertension and Regulation of Blood Pressure
Hypertension V: Nursing Management
Hypertension II: Pathophysiology
Antihypertensive Drugs: Direct Renin Inhibitors